Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Cash from Investing Activities (2016 - 2025)

Anaptysbio (ANAB) has disclosed Cash from Investing Activities for 10 consecutive years, with $73.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities rose 350.03% year-over-year to $73.5 million, compared with a TTM value of $228.0 million through Dec 2025, up 139.03%, and an annual FY2025 reading of $228.0 million, up 139.03% over the prior year.
  • Cash from Investing Activities was $73.5 million for Q4 2025 at Anaptysbio, down from $103.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $103.3 million in Q3 2025 and bottomed at -$312.9 million in Q1 2022.
  • Average Cash from Investing Activities over 5 years is $5.6 million, with a median of $26.1 million recorded in 2022.
  • The sharpest move saw Cash from Investing Activities plummeted 1953.64% in 2021, then soared 1590.7% in 2025.
  • Year by year, Cash from Investing Activities stood at -$66.7 million in 2021, then soared by 132.23% to $21.5 million in 2022, then skyrocketed by 128.77% to $49.2 million in 2023, then plummeted by 159.77% to -$29.4 million in 2024, then soared by 350.03% to $73.5 million in 2025.
  • Business Quant data shows Cash from Investing Activities for ANAB at $73.5 million in Q4 2025, $103.3 million in Q3 2025, and $36.4 million in Q2 2025.